Researchers theorized that owning the imaging machine—allowing practices to collect the “technical component” of reimbursement, in addition to the “professional” fee for reading the scans—could shelter groups from market forces.
A new analysis of the U.S. Food and Drug Administration’s artificial intelligence-enabled medical device database details how the technology’s regulatory standing has changed in recent years.
New findings suggest that embolization may offer better short- and long-term outcomes than nephrectomy for initially stable patients with such injuries.
“Our goal is to build a strong evidence base for proactive, preventive healthcare through collaborative, clinically grounded research," says the company's head of research.
Harrison.ai recently completed a $112M Series C financing round, which placed the company’s value at approximately $551 million (USD), Forbes Australia reports.
Many know Sol Radiology as the Southern California-based practice that, in this decade, grew from three radiologists to 45 in only three years. But other key indicators of Sol’s development might be the pieces from which presently small practices stand to learn the most.
